Needham & Company
-
Needham & Company Assumes Neurocrine Bio. (NBIX) at Hold
-
Pre-Open Stock Movers 12/23: (OCGN) (UAVS) (SUPN) (CLNE) (CLRB) (FUBO) (NKLA) (more...)
-
Companies with NDRs 08/28
-
Needham & Company Downgrades Neurocrine Bio. (NBIX) to Hold
-
Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & Company
-
Neurocrine Biosciences (NBIX)
-
Neurocrine Bio. (NBIX) PT Raised to $125 at Needham & Company
-
Neurocrine Biosciences (NBIX): Thoughts After KOL Call On Endometriosis and Uterine Fibroids - Needham
-
Neurocrine Bio. (NBIX) PT Raised to $110 at Needham & Company on Elagolix UF Phase 3 Data and Opicapone NDA Path
-
Neurocrine Bio. (NBIX) PT Raised to $95 at Needham & Company on Strength of Ingrezza Launch
-
Neurocrine Biosciences (NBIX): Strong Ingrezza Launch Continues - Needham
-
Neurocrine Biosciences (NBIX): Cutting PT After Tourette Endpoint Miss - Needham
-
Needham and Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX); 'FDA Approves Ingrezza, Launch Moved up to May'
-
Neurocrine Biosciences (NBIX): KOL Call Implies Ingrezza Approval in '17 - Needham
-
Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 Catalyst
-
Needham & Company Remains Bullish on Neurocrine Biosciences (NBIX) Following FDA Announcement
-
Needham & Company Starts Neurocrine Bio. (NBIX) at Buy
-
Pre-Open Stock Movers 1/8: (PATH) (FRX) (MU) Higher; (TCS) (JCP) (TWTR) Lower (more...)
-
Pre-Open Stock Movers 9/10: (INO) (FIVE) (NKE) Higher; (MODN) (NBIX) (CCXI) Lower (more...)
-
After-Hours Stock Movers 9/9: (FIVE) (FLOW) (PANW) Higher; (NBIX) (MODN) (PBY) Lower (more...)